Depreciation & Amortization
The latest quarterly d&a is $40.90 Million with a quarter-over-quarter change of -4.22%. Depreciation and Amortization (D&A) is a non-cash expense that allocates the cost of tangible and intangible assets over their useful lives.
EW D&A
Reported quarterly depreciation and amortization; no daily interpolation.
Current D&A
$40.90M
$40.90 Million
Quarter-over-Quarter Change
-4.22%
vs. $42.70M prior quarter
Historical Data
96
Quarters of data available
Quarterly D&A History
| Period | D&A | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $40.90M | $-1.80M | -4.22% |
| Q4 2025 | $42.70M | +$3.50M | +8.93% |
| Q3 2025 | $39.20M | +$1.10M | +2.89% |
| Q2 2025 | $38.10M | +$1.50M | +4.10% |
| Q1 2025 | $36.60M | $-6.00M | -14.08% |
| Q4 2024 | $42.60M | +$8.10M | +23.48% |
| Q3 2024 | $34.50M | $-5.10M | -12.88% |
| Q2 2024 | $39.60M | +$1.10M | +2.86% |
| Q1 2024 | $38.50M | +$1.80M | +4.90% |
| Q4 2023 | $36.70M | $-200,000 | -0.54% |
| Q3 2023 | $36.90M | +$800,000 | +2.22% |
| Q2 2023 | $36.10M | +$900,000 | +2.56% |
| Q1 2023 | $35.20M | $-200,000 | -0.56% |
| Q4 2022 | $35.40M | +$0 | 0.00% |
| Q3 2022 | $35.40M | +$1.30M | +3.81% |
| Q2 2022 | $34.10M | $-600,000 | -1.73% |
| Q1 2022 | $34.70M | +$1.70M | +5.15% |
| Q4 2021 | $33.00M | $-600,000 | -1.79% |
| Q3 2021 | $33.60M | $-2.20M | -6.15% |
| Q2 2021 | $35.80M | +$3.40M | +10.49% |
| Q1 2021 | $32.40M | $-200,000 | -0.61% |
| Q4 2020 | $32.60M | +$7.00M | +27.34% |
| Q3 2020 | $25.60M | +$1.10M | +4.49% |
| Q2 2020 | $24.50M | +$0 | 0.00% |
| Q1 2020 | $24.50M | +$600,000 | +2.51% |
| Q4 2019 | $23.90M | +$800,000 | +3.46% |
| Q3 2019 | $23.10M | +$7.10M | +44.38% |
| Q2 2019 | $16.00M | $-10.30M | -39.16% |
| Q1 2019 | $26.30M | +$6.40M | +32.16% |
| Q4 2018 | $19.90M | +$700,000 | +3.65% |
| Q3 2018 | $19.20M | +$0 | 0.00% |
| Q2 2018 | $19.20M | +$100,000 | +0.52% |
| Q1 2018 | $19.10M | $-2.10M | -9.91% |
| Q4 2017 | $21.20M | +$500,000 | +2.42% |
| Q3 2017 | $20.70M | +$1.80M | +9.52% |
| Q2 2017 | $18.90M | $-2.20M | -10.43% |
| Q1 2017 | $21.10M | +$2.00M | +10.47% |
| Q4 2016 | $19.10M | +$900,000 | +4.95% |
| Q3 2016 | $18.20M | +$200,000 | +1.11% |
| Q2 2016 | $18.00M | +$2.10M | +13.21% |
| Q1 2016 | $15.90M | +$1.40M | +9.66% |
| Q4 2015 | $14.50M | $-4.00M | -21.62% |
| Q3 2015 | $18.50M | +$1.70M | +10.12% |
| Q2 2015 | $16.80M | +$800,000 | +5.00% |
| Q1 2015 | $16.00M | $-2.30M | -12.57% |
| Q4 2014 | $18.30M | +$300,000 | +1.67% |
| Q3 2014 | $18.00M | +$1.90M | +11.80% |
| Q2 2014 | $16.10M | $-100,000 | -0.62% |
| Q1 2014 | $16.20M | $-2.60M | -13.83% |
| Q4 2013 | $18.80M | +$300,000 | +1.62% |
| Q3 2013 | $18.50M | +$2.40M | +14.91% |
| Q2 2013 | $16.10M | +$800,000 | +5.23% |
| Q1 2013 | $15.30M | +$200,000 | +1.32% |
| Q4 2012 | $15.10M | +$700,000 | +4.86% |
| Q3 2012 | $14.40M | +$400,000 | +2.86% |
| Q2 2012 | $14.00M | +$200,000 | +1.45% |
| Q1 2012 | $13.80M | $-1.00M | -6.76% |
| Q4 2011 | $14.80M | +$900,000 | +6.47% |
| Q3 2011 | $13.90M | $-900,000 | -6.08% |
| Q2 2011 | $14.80M | +$300,000 | +2.07% |
| Q1 2011 | $14.50M | $-900,000 | -5.84% |
| Q4 2010 | $15.40M | +$2.00M | +14.93% |
| Q3 2010 | $13.40M | $-300,000 | -2.19% |
| Q2 2010 | $13.70M | $-300,000 | -2.14% |
| Q1 2010 | $14.00M | $-200,000 | -1.41% |
| Q4 2009 | $14.20M | $-1.20M | -7.79% |
| Q3 2009 | $15.40M | +$500,000 | +3.36% |
| Q2 2009 | $14.90M | +$700,000 | +4.93% |
| Q1 2009 | $14.20M | $-100,000 | -0.70% |
| Q4 2008 | $14.30M | +$500,000 | +3.62% |
| Q3 2008 | $13.80M | $-200,000 | -1.43% |
| Q2 2008 | $14.00M | +$500,000 | +3.70% |
| Q1 2008 | $13.50M | $-200,000 | -1.46% |
| Q4 2007 | $13.70M | $-300,000 | -2.14% |
| Q3 2007 | $14.00M | +$300,000 | +2.19% |
| Q2 2007 | $13.70M | +$300,000 | +2.24% |
| Q1 2007 | $13.40M | $-1.20M | -8.22% |
| Q4 2006 | $14.60M | +$800,000 | +5.80% |
| Q3 2006 | $13.80M | $-600,000 | -4.17% |
| Q2 2006 | $14.40M | +$400,000 | +2.86% |
| Q1 2006 | $14.00M | $-400,000 | -2.78% |
| Q4 2005 | $14.40M | +$400,000 | +2.86% |
| Q3 2005 | $14.00M | $-200,000 | -1.41% |
| Q2 2005 | $14.20M | +$600,000 | +4.41% |
| Q1 2005 | $13.60M | $-1.00M | -6.85% |
| Q4 2004 | $14.60M | $-700,000 | -4.58% |
| Q3 2004 | $15.30M | +$2.40M | +18.60% |
| Q2 2004 | $12.90M | +$0 | 0.00% |
| Q1 2004 | $12.90M | +$1.30M | +11.21% |
| Q4 2003 | $11.60M | $-300,000 | -2.52% |
| Q3 2003 | $11.90M | +$600,000 | +5.31% |
| Q2 2003 | $11.30M | +$500,000 | +4.63% |
| Q1 2003 | $10.80M | $-200,000 | -1.82% |
| Q4 2002 | $11.00M | +$900,000 | +8.91% |
| Q3 2002 | $10.10M | +$500,000 | +5.21% |
| Q2 2002 | $9.60M | — | — |
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian